GENEWIZ receives investment from OrbiMed for growth in its DNA sequencing, gene synthesis
Genomics services provider, GENEWIZ, continues to grow with new financing, but it is unclear how much was raised in the OrbiMed-led round.
OrbiMed announces closing of next venture capital fund with $950M
OrbiMed's newest funding is planned to go toward companies focusing on oncology, central nervous system disease and gene editing.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Healthcare venture firm OrbiMed launching $300M Israeli investment fund
If it's anything like its first fund, OrbiMed's new Israeli investment fund will invest $5 million to $20 million in each of 12 to 15 companies - much like the first fund.
Therachon, achondroplasia therapy developer, closes $35M Series A
Therachon has raised significant funding to support clinical proof of its soluable form of human fibroblast growth factor receptor 3. This could treat achondroplasia, a genetic mutation that is the leading cause of dwarfism.
OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014
OrbiMed has closed its largest venture capital healthcare fund to date as two partners predict a resurgence in biotech investment next year. The robust reception biotech initial public offerings have received this year is fueling this trend, according to Jonathan Silverstein, a general partner and co-head of global private equity at the firm. The $735 […]